8 assets in Carcinosarcoma

Therapeutic assets addressing Carcinosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Carcinosarcoma	Blueprint Medicines Corporation	P3	BB (66)
Ipilimumab Carcinosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Carcinosarcoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Atezolizumab Carcinosarcoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Cirtociclib Carcinosarcoma	Blueprint Medicines Corporation	P1	CC (43)
Fulvestrant Carcinosarcoma	Blueprint Medicines Corporation	P1	CC (43)
Ribociclib Carcinosarcoma	Blueprint Medicines Corporation	P1	CC (43)
Dordaviprone Carcinosarcoma	UNC Lineberger Comprehensive Cancer Center	P1	C (39)